Serum IFI16 and anti-IFI16 Antibodies in Psoriatic Arthritis

OBJECTIVE:

The nuclear interferon-inducible protein 16 (IFI16) and anti-IFI16 antibodies have been detected in subjects with several rheumatic diseases, often correlating with disease severity, and we herein investigated their prevalence and clinical associations in psoriatic arthritis (PsA) compared to psoriasis (Pso).

METHODS:

We tested sera and synovial fluids of patients with PsA for IFI16 protein levels by capture ELISA and for anti-IFI16 IgG and IgA by ELISA, protein radio-immunoprecipitation and immunoprecipitation-Western blot of IgG. Sera from patients with Pso and healthy subjects were used as controls, and in a subgroup of patients with PsA we also studied sera after treatment with etanercept.

RESULTS:

IFI16 was detectable in the sera of 66% of patients with Pso, 46% of PsA, and 19% of controls. Among PsA cases, 51% of IFI16-positive cases had elevated levels of C-reactive protein (CRP) compared to 31% of patients with undetectable IFI16. Anti-IFI16 of both IgG and IgA isoforms were detected with significantly higher frequency in PsA and Pso compared to healthy controls, with higher IgG titers in patients with elevated CRP (p=0.015). Immunoprecipitation confirmed the presence of anti-IFI16 IgG antibodies and these preferentially recognized epitopes outside the N-terminus of the protein. Lastly, IFI16 was detected in 1/7 and anti-IFI16 in 3/7 synovial fluids from patients with PsA.

CONCLUSION:

IFI16 and anti-IFI16 are detectable in serum and synovial fluid of PsA patients, especially in case of elevated CRP.

 2019 Sep 30. doi: 10.1111/cei.13376. [Epub ahead of print]